AstraZeneca and Ionis entered a global strategic collaboration to develop and commercialize eplontersen for transthyretin amyloidosis. AstraZeneca paid $200M upfront, up to $485M in conditional regulatory payments, plus up to $2.9B in sales-related milestones, totaling ~$3.585B. AZ leads ex-US (excluding Latin America); jointly developed/commercialized in US.